Diagnos $ADK IRIS, a New Look #Vision Group Company, Teams up with Diagnos in a Multi-Year Agreement to Implement #AI #Technology with Support from INVEST-AI Program

Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce the signing of a multi-year agreement with IRIS The Visual Group (1990) Inc. (“IRIS”), creating a world leading platform launch for the deployment and enhancement of Artificial Intelligence (“AI”) based tests, screening for vascular changes in the retina for optometry clinics.

This milestone agreement with IRIS constitutes a major breakthrough for DIAGNOS’ path to continued global commercialization of its technology solutions.

Initially, implementation of AI at IRIS will cover the province of Quebec in a multi-step approach as per the agreement with the INVEST-AI program. The INVEST-AI Program is managed by IVADO Labs, who receives financial contributions from the Government of Quebec to facilitate the transfer of AI to industry.

“IRIS continues to be at the forefront of implementing technology driven solutions for clinical optometry and optical retail. The combination of technological advancement and clinical experience will help elevate the health care experience and improve patient outcomes. Artificial intelligence will raise our standard when it comes to quality of care and we are eager to collaborate with DIAGNOS,” said Eric Babin, President of IRIS.

In addition, DIAGNOS has entered into a 7-year agreement with New Look Vision Group Inc. (“New Look Vision”), IRIS’ parent company. The New Look Vision network totals 406 locations operating across North America. Outside of the initial implementation, supported by the INVEST-AI Program, this agreement further supports the development and deployment of AI across the broader network.

DIAGNOS algorithms installed in our data center in Montreal will examine the retina images of patients. Patient’s retina images are transmitted using a secure internet connection. DIAGNOS then provides the results of the AI assisted examination back to the optometrist in the form of a report. The optometrist may then use the results of the report to assist in managing treatment and potential referral. DIAGNOS is reimbursed based on a click fee per patient which includes 2 pictures of the retina (left eye and right eye).

“We are extremely pleased to enter into this major agreement with IRIS and New Look Vision, a market leader in North America with more than 400 optical stores. IRIS and New Look Vision are ideal industry partners for the rapid implementation of DIAGNOS’ technologies,” stated André Larente, President of DIAGNOS.

Introduction of AI in medical imaging has changed the market dynamics in recent years and is anticipated to massively influence the growth in the near future. DIAGNOS is committed to develop and market AI-based solutions in the field of medical imaging diagnosis, providing key decision-making support. Though the AI adoption is in the early phase in retinal technologies, rising demand for accuracy, efficiency, and patient safety is anticipated to significantly boost the adoption of DIAGNOS’ AI-enabled medical imaging over the next several years.

“Clinics, optical stores, and diagnostic and research centers are expected to emerge as crucial end users of our image analysis solutions, owing to rising demand for our extremely efficient solutions for better patient outcomes,” said André Larente. “In the future, these segments will account for larger DIAGNOS revenue shares as they increasingly rely on imaging services like CARA (Computer Assisted Retina Analysis), creating significant growth potential for DIAGNOS during its recently launched monetization strategy. Adoption of technologically advanced products such as our proprietary multimodality imaging platforms and benefits associated with the use of our systems, such as high-resolution imaging, convenient use, and flexibility, are contributing to constantly growing demand. Therefore, DIAGNOS is very actively continuing its global roll-out activities and the introduction of even further technologically advanced product updates and the advent of efficient information management systems are expected to drive the market growth in the coming years on a global scale. DIAGNOS has successfully started to transition to its international commercialization strategy, effectively navigating the regulatory landscape, in a highly competitive market, enabling its commercial products to get to market faster than the competition. Launching DIAGNOS’ global sales campaign in the first half of 2021 has allowed the Company to achieve very tangible results for its shareholders already this year, including, but not limited to, the New Look Vision agreement. DIAGNOS is targeting to be cash flow positive by the end of 2021.”

About IRIS and New Look Vision:

IRIS was founded in 1990 in Quebec. Since that time, IRIS has developed into the largest network of optometrists, opticians and ophthalmologists operating under the same banner across Canada. The company’s locations combine clinical optometry and optical retail to provide a unique concept and a commitment to offering top quality products and services in the field of eyecare. For additional information please visit www.iris.ca or consult our LinkedIn page.

New Look Vision is the leading provider of eye care products and services across Canada and entered the United States market in 2020. The Company has retail sales of optical products which can be grouped into four principal categories: (i) prescription and non-prescription eyewear, (ii) contact lenses, (iii) sunglasses, protective eyewear and reading glasses, and (iv) accessories, such as cleaning products for eyeglasses and contact lenses. The Company’s network of stores totals 406 locations. Certain prescription lenses are processed at the Company’s laboratory facility, located in Ville St-Laurent, Québec. For additional information please visit www.newlookvision.ca.

About DIAGNOS:

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

This news release contains forward-looking information. There can be no assurance that forward-lookinginformation will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Mr. André Larente,
PresidentDIAGNOS Inc.
Tel: +1-450-678-8882 ext. 224
Corporate Communications:
Nancy Massicotte
IR Pro Communications Inc.
Dir: +1 604-507-3377TF: 1-866-503-3377

Diagnos $ADK $DGNOF Enters into Exclusive Distribution Agreement to Access Massive Global Healthcare Market in DACH Countries and Central Europe of Over 140 Million People

Diagnos Inc. TSXV-ADK OTCQB: DGNOF a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of an exclusive distribution agreement with Diagnos Europe GmbH (“Diagnos Europe”), a new partner for DIAGNOS to tackle the strategically important DACH countries in the European market (Germany, Austria, Switzerland) and the surrounding countries Poland, Luxembourg and Liechtenstein in order to prepare a successful market entry for the Company’s products and services in Central Europe, a crucial territory for DIAGNOS with a significant market potential in access of more than 140 million people.

DACH is an abbreviation and D stands for Deutschland (Germany), A, Austria, and CH, Confoederatio Helvetica, (Switzerland). Therefore, it refers to the mostly German-speaking center of Europe. The DACH economy is one of the most stable in the entire world since the end of World War II and it is by far the largest and most promising market for IT and AI in Europe. Diagnos Europe is fully specialized on go-to-market strategies and services in the DACH countries and have developed for DIAGNOS a variety of market entry strategies offering the Company a practical and effective launch pad into the DACH market. 

 Just as the DACH region has become established as Europe’s most important region for the optical market, DIAGNOS will be benefiting from the forthcoming market entry developments and has in addition that long tapping into European potential. The German market, in particular, plays a leading role in the optical industry and thus also for the Company and Diagnos Europe in terms of preparing the implementation of specific sales activities. Alongside the French market, which DIAGNOS is also targeting at the same time, the German-speaking market is the most important in Europe and also the most interesting for the company as a result of its stable growth rates over the past several years. For 2019, the German optical industry was able to record its most successful financial year in a decade, far outperforming other European markets (total sales compared to 2018 were up by 5.4% at EUR 4.7 billion; 2019 thus exceeding all expectations and a continuation of the growth trend that has persisted since 2011. Opticians and optometrists have continuously been able to look forward to a further increase in turnover, which rose to almost EUR 6.5 billion in 2019 and even more in 2020).

Read more:  http://www.diagnos.ca/wp-content/uploads/2021/04/DIAGNOS-Enters-into-Exclusive-Distribution-Agreement-to-Access-Massive-Global-Healthcare-Market-in-DACH-Countries.pdf

@Diagnos $ADK $DGNOF Uses #AI and #Telemedicine to Scan your #Eye for #Health Issues in 16 Countries

In a world where companies toss the term ‘artificial intelligence’ around whenever the office intern figures out how to get a spreadsheet pie chart to update automatically, it’s nice to see a company utilizing actual AI and machine learning in a manner that involves actual intelligence and learning.

Diagnos (ADK.V) is a health tech deal that scans your eye for evidence of health issues, using AI to deliver fast, inexpensive detection that can be used to scan an entire population. 

Click Link for Article:  Diagnos Uses AI and Telemedicine to Scan Your Eye for Health Issues in 16 Countries

http://www.diagnos.ca

 

Diagnos Inc. $ADK and the 3rd Largest #Optical Retailer in Costa Rica Piloting CARA and its #Telemedicine #Technology

Diagnos Inc. $ADK and the 3rd Largest #optical Retailer in Costa Rica Piloting CARA and its #telemedicine #technology

#Healthcare #diabetes #retinaldisease #AI #artificialintelligence #Hypertension #stroke #deeplearning

Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of a contract with Óptica Central, the third largest optical chain store in Costa Rica for implementation of CARA across Costa Rica.

“Óptica Central, in collaboration with Aselcom, DIAGNOS’ distributor, are pleased to start screening the population across our optical stores by providing DIAGNOS’ proven AI solution for early detection of eye illnesses, such as Diabetic Retinopathy, as well as preventing blindness caused by diabetes.   There is no doubt that DIAGNOS’ experience in Costa Rica, and in other Latin American countries, has been at the forefront in proving its service with their remarkable technology,” said Mr. Jefrey Salas, CEO of Óptica Central.

“At DIAGNOS we have made our mark in different parts of the world, in collaboration with our partners and different stakeholders, where our AI technology and experience for serving patients has set the standard. We know that Diabetic Retinopathy has become the main cause of blindness worldwide occurring in patients aged 20-64 years. Costa Rica is no different from other countries, with almost 15% of its population over 20 having diabetes, with less than 11% diagnosed. At least 35% have been identified with Diabetic Retinopathy within the diabetic population and 10% are in jeopardy of having severe retinopathy that will affect their vision. Our technology is helping now, through Óptica Central, to fill this gap,” said Mr. Andre Larente, President of DIAGNOS.

About Óptica Central
Founded in July 1983, Óptica Central, located in Alajuela, has become a pioneer in the visual health service offering optics and optometry services. Since its inception, it has been contributing to the visual health of the population with affordable prices and a variety of products such as: Specialties Medical Center, 8 Service Centers / Opticians in the metropolitan area, with more than 40 stores located in national territory of Costa Rica.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.com and www.sedar.com

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224

Diagnos Inc. $ADK AI Image-Based Diagnosis – Commercializing their CARA #Technology

Expanding globally in the AI image based diagnosis sector, Diagnos is actively commercializing their CARA technology.

Diagnos TSXV-ADK is an AI health care company using non-invasive scanning technology done through the eyeball to detect retinal diabetes and hypertension. They are FDA approved, ISO certified and Health Canada approved.

https://investorintel.com/markets/biotech-healthcare/biotech-intel/expanding-globally-in-the-ai-image-based-diagnosis-sector-diagnos-is-actively-commercializing-their-cara-technology/